Palpex Pharmaceuticals products and prices in Pakistan
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Follow price changes 🔒 Company report (Pharma Pro)Private pharmaceutical manufacturer · Karachi · Pakistan
Karachi pharmaceutical manufacturer established in 2017 with general and cephalosporin oral and injectable manufacturing capabilities.
Palpex Pharmaceuticals products in Pakistan
Palpex Pharmaceuticals pvt ltd has 42 medicine presentations registered in Pakistan under 21 brands, covering 15 generic medicines. Most of its products are in Anti-infectives, Vitamins, minerals & nutrition and Gastrointestinal & hepatology. Its brands with the most registered strengths and packs are Cynith (Ceftriaxone), Palthro (Azithromycin), Cipropal (Ciprofloxacin) and Keynom (Omeprazole). 42 products have an official DRAP price on MedInfoBase. See all 21 brands A to Z
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Palpex Pharmaceuticals (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- Plot FD-46-A8, Street 1, Sector 38, Korangi Creek Industrial Park, Karachi 74900, Pakistan · 74900
- Website
- palpex.com ↗
- Phone
- +92 21 38893900-02
- info@palpex.com
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
See where Palpex Pharmaceuticals pvt ltd is priced against the market
36 of its products have like-for-like competitors. Pharma Pro shows how many are priced below, near or above the market median, the company's overall price position, and product-by-product examples.
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
🔒 3 more overlapping companies, with shared-generic detail, in Pharma Pro. Unlock
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| B-Art 20 | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 16's | 082295 | PKR 592.04 | PKR 37.00/tablet | 🔒 Pharma Pro |
| B-Art Dry | Artemether + Lumefantrine | 15 mg/5 mL + 90 mg/5 mL | Dry suspension | 60ml | 082948 | PKR 326.37 | PKR 5.44/mL | 🔒 Pharma Pro |
| B-Art Dry | Artemether + Lumefantrine | 15 mg/5 mL + 90 mg/5 mL | Dry suspension | 30ml | 082948 | PKR 166.51 | PKR 5.55/mL | 🔒 Pharma Pro |
| B-Art DS 40 | Artemether + Lumefantrine | 40 mg + 240 mg | Tablet | 8's | 082296 | PKR 488.43 | PKR 61.05/tablet | 🔒 Pharma Pro |
| B-Art Forte | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 6,s | 082297 | PKR 610.54 | PKR 101.76/tablet | 🔒 Pharma Pro |
| B-Ther | Artemether | 80 mg/mL | Injection | 1mlx5's | 089107 | PKR 888.05 | PKR 177.61/mL | 🔒 Pharma Pro |
| Cipropal | Ciprofloxacin | 250 mg | Tablet | 10's | 082931 | PKR 240.52 | PKR 24.05/tablet | 🔒 Pharma Pro |
| Cipropal | Ciprofloxacin | 500 mg | Tablet | 10's | 082932 | PKR 397.77 | PKR 39.78/tablet | 🔒 Pharma Pro |
| Cipropal | Ciprofloxacin | 200 mg/100 mL | Solution for infusion | 100ml | 082949 | PKR 185.01 | PKR 1.85/mL | No comparator |
| Cynith | Ceftriaxone | 250 mg | Injection | 1's | 082956 | PKR 186.86 | PKR 186.86/vial/unit | 🔒 Pharma Pro |
| Cynith | Ceftriaxone | 500 mg | Injection | 1's | 082957 | PKR 314.51 | PKR 314.51/vial/unit | 🔒 Pharma Pro |
| Cynith | Ceftriaxone | 500 mg | Injection | 1's | 082960 | PKR 314.51 | PKR 314.51/vial/unit | 🔒 Pharma Pro |
| Cynith | Ceftriaxone | 1 g | IV injection | 1's | 082961 | PKR 593.88 | PKR 593.88/vial/unit | 🔒 Pharma Pro |
| D-Tan | Cholecalciferol | 5 mg/mL (200,000 IU/mL) | Injection | 1's | 082971 | PKR 203.53 | PKR 203.53/vial/unit | 🔒 Pharma Pro |
| D-Tan | Cholecalciferol | 200,000 IU/mL | Injection | 5's | 082971 | PKR 864.00 | PKR 172.80/vial/unit | 🔒 Pharma Pro |
| Dexnor Capsule 30mgRegistry verified | Dexlansoprazole (as dual delayed release pellets) | — | — | — | 133019Official source ↗ | No indexed price | — | — |
| Dexnor Capsule 60mgRegistry verified | Dexlansoprazole (as dual delayed release pellets) | — | — | — | 133020Official source ↗ | No indexed price | — | — |
| Fincef | Cefixime | 400 mg | Capsule | 5's | 082943 | PKR 564.17 | PKR 112.83/capsule | 🔒 Pharma Pro |
| Fincef Dry | Cefixime | 100 mg/5 mL | Dry suspension | 30ml | 082946 | PKR 314.83 | PKR 10.49/mL | 🔒 Pharma Pro |
| Fincef DS Dry | Cefixime | 200 mg/5 mL | Dry suspension | 30ml | 092895 | PKR 385.29 | PKR 12.84/mL | 🔒 Pharma Pro |
| Keynom | Omeprazole | 20 mg | Capsule | 14's | 082936 | PKR 266.42 | PKR 19.03/capsule | 🔒 Pharma Pro |
| Keynom | Omeprazole | 40 mg | Capsule | 2x7's | 082937 | PKR 462.53 | PKR 33.04/capsule | 🔒 Pharma Pro |
| Keynom | Omeprazole | 40 mg | Powder for solution for IV infusion | 1's | 082953 | PKR 555.02 | PKR 555.02/vial/unit | No comparator |
| Ncopenem Injection 1g IVRegistry verified | Meropenem as Trihydrate Blended with Anhydrous Sodium Carbonate (Sterile) | — | — | — | 108954Official source ↗ | No indexed price | — | — |
| Ncopenem Injection 500mg IVRegistry verified | Meropenem as Trihydrate Blended with Anhydrous Sodium Carbonate (Sterile) | — | — | — | 108953Official source ↗ | No indexed price | — | — |
| Onism Capsule 500mgRegistry verified | Cefadroxil monohydrate eq to cefadroxil | — | — | — | 108645Official source ↗ | No indexed price | — | — |
| Palfepim Injection 500mgIM/IVRegistry verified | Cefepime (as hydrochloride) (with L-arginine) | — | — | — | 096226Official source ↗ | No indexed price | — | — |
| Palfer | Iron sucrose | 100 mg/5 mL | Injection | 5mlx5's | 082968 | PKR 2,728.90 | PKR 109.16/mL | 🔒 Pharma Pro |
| Palflox | Levofloxacin | 250 mg | Tablet | 10's | 082929 | PKR 462.53 | PKR 46.25/tablet | 🔒 Pharma Pro |
| Palflox | Levofloxacin | 500 mg | Tablet | 10's | 082930 | PKR 769.64 | PKR 76.96/tablet | 🔒 Pharma Pro |
| Palflox | Levofloxacin | 500 mg/100 mL | Solution for infusion | 100ml | 082950 | PKR 462.53 | PKR 4.63/mL | No comparator |
| Palfotax | Cefotaxime | 250 mg | Injection | 1's | 082962 | PKR 105.67 | PKR 105.67/vial/unit | 🔒 Pharma Pro |
| Palfotax | Cefotaxime | 500 mg | Injection | 1's | 082963 | PKR 159.25 | PKR 159.25/vial/unit | 🔒 Pharma Pro |
| Palfotax | Cefotaxime | 1 g | IV injection | 1's | 082964 | PKR 286.42 | PKR 286.42/vial/unit | 🔒 Pharma Pro |
| Palmizol | Metronidazole | 500 mg/100 mL | Injection | 100ml | 082951 | PKR 144.31 | PKR 1.44/mL | 🔒 Pharma Pro |
| Palnet-M Tablet 5mgRegistry verified | Norethisterone | — | — | — | 133220Official source ↗ | No indexed price | — | — |
| Palogylut TabletRegistry verified | Estradiol Valerate , Norgestrel | — | — | — | 122385Official source ↗ | No indexed price | — | — |
| Palthro | Azithromycin | 250 mg | Capsule | 6's | 082938 | PKR 283.06 | PKR 47.18/capsule | 🔒 Pharma Pro |
| Palthro | Azithromycin | 200 mg/5 mL | Dry suspension | 30ml | 082947 | PKR 598.33 | PKR 19.94/mL | 🔒 Pharma Pro |
| Palthro | Azithromycin | 200 mg/5 mL | Dry suspension | 15ml | 082947 | PKR 305.27 | PKR 20.35/mL | 🔒 Pharma Pro |
| Palthro | Azithromycin | 500 mg | Powder for solution for infusion | 1's | 082955 | PKR 370.03 | PKR 370.03/vial/unit | No comparator |
| Palxamic | Tranexamic acid | 250 mg | Capsule | 20's | 082941 | PKR 240.52 | PKR 12.03/capsule | 🔒 Pharma Pro |
| Palxamic | Tranexamic acid | 500 mg/5 mL | Injection | 5mlx5's | 096225 | PKR 786.29 | PKR 31.45/mL | 🔒 Pharma Pro |
| Palxamic | Tranexamic acid | 500 mg | Capsule | 20's | 096997 | PKR 462.53 | PKR 23.13/capsule | 🔒 Pharma Pro |
| Palzidime | Ceftazidime | 250 mg | Injection | 1's | 089354 | PKR 159.94 | PKR 159.94/vial/unit | 🔒 Pharma Pro |
| Palzidime | Ceftazidime | 500 mg | IV/IM injection | 1's | 089355 | PKR 243.30 | PKR 243.30/vial/unit | 🔒 Pharma Pro |
| Palzidime | Ceftazidime | 1 g | Injection | 1's | 089356 | PKR 456.99 | PKR 456.99/vial/unit | 🔒 Pharma Pro |
| Palzon | Ceftriaxone | 250 mg | IV injection | 1's | 082959 | PKR 186.86 | PKR 186.86/vial/unit | 🔒 Pharma Pro |
| Palzon (I.M) Injection 1gm Powder for Solution forRegistry verified | Ceftriaxone (as sodium) | — | — | — | 082958Official source ↗ | No indexed price | — | — |
| Pexpal Tablet 10mgRegistry verified | Dydrogestrone | — | — | — | 133257Official source ↗ | No indexed price | — | — |
All 21 Palpex Pharmaceuticals brands in Pakistan
- B-Art 20 Artemether + Lumefantrine · 20 mg + 120 mg tablet
- B-Art Dry Artemether + Lumefantrine · 15 mg/5 mL + 90 mg/5 mL suspension
- B-Art DS 40 Artemether + Lumefantrine · 40 mg + 240 mg tablet
- B-Art Forte Artemether + Lumefantrine · 80 mg + 480 mg tablet
- B-Ther Artemether · 80 mg/mL injection
- Cipropal Ciprofloxacin · 200 mg/100 mL infusion, 250 mg tablet, 500 mg tablet
- Cynith Ceftriaxone · 1 g injection, 250 mg injection, 500 mg injection
- D-Tan Cholecalciferol · 200,000 IU/mL injection, 5 mg/mL (200,000 IU/mL) injection
- Fincef Cefixime · 400 mg capsule
- Fincef Dry Cefixime · 100 mg/5 mL suspension
- Fincef DS Dry Cefixime · 200 mg/5 mL suspension
- Keynom Omeprazole · 20 mg capsule, 40 mg infusion, 40 mg capsule
- Palfer Iron sucrose · 100 mg/5 mL injection
- Palflox Levofloxacin · 250 mg tablet, 500 mg tablet, 500 mg/100 mL infusion
- Palfotax Cefotaxime · 1 g injection, 250 mg injection, 500 mg injection
- Palmizol Metronidazole · 500 mg/100 mL injection
- Palthro Azithromycin · 200 mg/5 mL suspension, 250 mg capsule, 500 mg infusion
- Palxamic Tranexamic acid · 250 mg capsule, 500 mg capsule, 500 mg/5 mL injection
- Palzidime Ceftazidime · 1 g injection, 250 mg injection, 500 mg injection
- Palzon Ceftriaxone · 250 mg injection
- Sunatex Artesunate · 120 mg injection, 60 mg injection
Palpex Pharmaceuticals: common questions
How many products does Palpex Pharmaceuticals have in Pakistan?
Palpex Pharmaceuticals pvt ltd has 42 registered medicine presentations in Pakistan, sold under 21 brands and covering 15 generic medicines.
What are the main brands of Palpex Pharmaceuticals?
By number of registered strengths and packs, its largest brands are Cynith (Ceftriaxone), Palthro (Azithromycin), Cipropal (Ciprofloxacin), Keynom (Omeprazole) and Palflox (Levofloxacin). This is not a sales ranking.
Which therapy areas does Palpex Pharmaceuticals cover?
The most products are in Anti-infectives (33), Vitamins, minerals & nutrition (3), Gastrointestinal & hepatology (3) and Hematology & thrombosis (3).
Where can I see Palpex Pharmaceuticals medicine prices?
Open any brand in the list above for its official DRAP price, pack sizes, price history and other brands of the same medicine.
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.